Catalent

66 articles about Catalent

• Catalent, Inc. Announces Third Quarter Fiscal Year 2022 Earnings Conference Webcast

  4/15/2022

  Catalent today announced that it will release financial results for the third quarter of fiscal year 2022 ended March 31, 2022, before the market open on Tuesday, May 3, 2022.

• Catalent, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum

  3/18/2022

  Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will virtually present at the KeyBanc Life Sciences & MedTech Investor Forum at 10:30 a.m. ET on March 23, 2022.

• TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement

  3/1/2022

  TFF Pharmaceuticals, Inc. and Catalent announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of TFF Pharmaceuticals’ patented Thin Film Freezing technology.

• Catalent, Inc. Reports Second Quarter Fiscal 2022 Results

  2/1/2022

  Catalent, Inc. today announced financial results for the second quarter of fiscal 2022, which ended December 31, 2021.

• Catalent, Inc. Announces Second Quarter Fiscal Year 2022 Earnings Conference Webcast

  1/21/2022

  Catalent today announced that it will release financial results for the second quarter of fiscal year 2022 ended December 31, 2021, before the market open on Tuesday, February 1, 2022.

• Catalent Announces Plan for Alessandro Maselli to Become New CEO Effective July 1, 2022

  1/5/2022

  Catalent today announced that its Board of Directors has appointed Alessandro Maselli, currently President and Chief Operating Officer, as the company’s next President and Chief Executive Officer, effective July 1, 2022.

• Catalent, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/3/2022

  Catalent announced that members of its executive leadership team will virtually present at the 40th Annual J.P. Morgan Healthcare Conference at 7:30 a.m. ET on January 10, 2022.

• BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn® Manufacturing

  12/7/2021

  BrainStorm Cell Therapeutics Inc. and Catalent today announced that the technology transfer for NurOwn® manufacturing at Catalent's facility has been finalized.

• Catalent, Inc. to Present at the Stephens Annual Investment Conference

  11/23/2021

  Catalent, Inc., an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world.

• Catalent, Inc. Reports First Quarter Fiscal 2022 Results

  11/2/2021

  Catalent, Inc. today announced financial results for the first quarter of fiscal 2022, which ended September 30, 2021.

• 

  Life Sciences Industry Sees Burst of Job and Facility Expansions in October

  10/28/2021

  The life sciences industry continues to be one of the fastest growing industries in the world as the end of the year draws near.

• Catalent Announces Upsizing and Pricing of Private Offering of Senior Unsecured Notes Due 2030

  9/23/2021

  Catalent, Inc. (“Catalent”) (NYSE: CTLT), today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), priced a private offering (the “Private Offering”) of $650 million in aggregate principal amount of 3.500% senior unsecured notes due 2030 (the “Notes”) at par, which represents an increase of $200 million from the offering size previously announced.

• Catalent Announces Launch of Private Offering of $450 Million of Senior Unsecured Notes Due 2030

  9/23/2021

  Catalent, Inc. today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), intends to offer, subject to market and other conditions, $450 million in aggregate principal amount of senior unsecured notes due 2030

• Catalent, Inc. to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

  9/7/2021

  Catalent, Inc. today announced that members of its executive leadership team will virtually present at the Morgan Stanley 19th Annual Global Healthcare Conference at 1:15 a.m. ET on September 9, 2021.

• Catalent, Inc. Reports Fourth Quarter Fiscal 2021 Results

  8/30/2021

  Catalent, Inc., the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and gene therapies; and consumer health products, announced financial results for the fourth quarter of fiscal 2021, which ended June 30, 2021.

• Catalent, Inc. Announces Fourth Quarter Fiscal Year 2021 Earnings Conference Webcast

  8/6/2021

  Catalent, Inc. today announced that it will release financial results for the fourth quarter of fiscal year 2021 ended June 30, 2021, before the market open on Monday, August 30, 2021.

• Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Based Target Initiative to Reduce Carbon Footprint

  8/3/2021

  Catalent, Inc. announced that, effective July 1, 2021, 97% of its electricity usage across its global network is being procured from renewable energy sources such as wind, solar, hydroelectric, and biomass.

• DisperSol and Catalent Collaborate to Establish KinetiSol® Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline

  8/2/2021

  DisperSol Technologies and Catalent announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products.

• Catalent, Inc. to Present at the Biopharma CEO Investor Forum

  6/4/2021

  Catalent, Inc., the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that John Chiminski, Chair and Chief Executive Officer, will virtually present at the Biopharma CEO Investor Forum at 9:45 a.m. ET on June 8, 2021.

• Catalent, Inc. to Present at the UBS Global Healthcare Virtual Conference

  5/21/2021

  Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the UBS Global Healthcare Virtual Conference at 11:00 a.m. ET on May 26, 2021.